Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Cureus|May 15, 2025
Reassessing Cisplatin Eligibility in Urothelial Carcinoma: A Retrospective Study on Dose Reduction StrategiesSatoshi Yamamoto, Koichiro Kurokawa, Koki Watanabe, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|December 13, 2025
Prognostic significance of nutritional and muscular indices in immune checkpoint inhibitor therapy for metastatic urothelial carcinoma: A preliminary studySatoshi Yamamoto, Keita Higa, Koichiro Kurokawa, et al.
International Urology and Nephrology|April 3, 2026
Tumor-draining lymph nodes as immunologic hubs: rethinking nodal surgery in the era of checkpoint blockade in urologic cancersSatoshi Yamamoto, Keita Higa, Koichiro Kurokawa, et al.
Geriatrics & Gerontology International|July 31, 2026
Full-Component Chart-Derived Lee Score, Upfront Androgen Receptor Signaling Inhibitor Selection, and Competing Mortality in Metastatic Hormone-Sensitive Prostate CancerKoichiro Kurokawa, Satoshi Yamamoto, Keita Higa, et al.
Anticancer Research|February 27, 2026
Severe Esophageal Ulceration With Enfortumab Vedotin Plus Pembrolizumab Therapy in Urothelial Carcinoma: A Case ReportHiroki Bamba, Satoshi Yamamoto, Keita Higa, et al.
Cancer Genetics|June 17, 2025
Efficacy of pembrolizumab in MSI-high and BRCA-positive castration-resistant prostate cancerKeita Higa, Satoshi Yamamoto, Koichiro Kurokawa, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|April 18, 2026
Predictive Factors for Operative Time and Blood Loss in Retroperitoneal Laparoscopic Adrenalectomy: A Single-Center ExperienceYusuke Imamura, Xue Zhao, Sanji Kanaoka, et al.
Cancer Letters|March 15, 2024
Chromatin activation with H3K36me2 and compartment shift in metastatic castration-resistant prostate cancerSanji Kanaoka, Atsushi Okabe, Manato Kanesaka, et al.
Cancer Science|April 24, 2024
The LAT1 inhibitor JPH203 suppresses the growth of castration-resistant prostate cancer through a CD24-mediated mechanismShinpei Saito, Keisuke Ando, Shinichi Sakamoto, et al.
Japanese Journal of Clinical Oncology|May 17, 2025
Clinical benefits of androgen receptor signaling inhibitors in patients with metastatic hormone-sensitive prostate cancer: real-world data from a multi-center studyYosuke Kinoshita, Yasutaka Yamada, Takuya Tsujino, et al.
Pageof 2